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Abstract: Cytomegalovirus (CMV) and the human tumor cell share the same objectives: escape the recognition and 
destruction by the immune system and establish a state of immune tolerance conducive for their development. For early 
tumor development, the escape of the first lines of defense of the immune surveillance is a critical step which determines 
survival or destruction. The presence of CMV on the tumor site and its involvement in carcinogenesis as initiator or 
promoter is increasingly documented. In this article, we highlight the similarity between mechanisms used by tumors and 
CMV to circumvent the immune defenses and evade from immune surveillance. We suggest that CMV and tumors help 
one another for their common objective. CMV gets shelter in immunologically poor environment of the tumor cells. In 
return CMV, by acting directly on the cancer cell and/or on the tumor microenvironment, provides the tumor cell the ways 
to promote its immune escape and development of immune tolerance. 
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INTRODUCTION 
  The theory of cancer immunosurveillance proposes that the 
immune system can detect and eliminate the developing tumors. 
There were a number of arguments in favor of the immune 
system’s efficiency to struggle against cancers such as the 
increased incidence of cancers in immunosuppressed patients, 
the correlation between intratumoral infiltrating T cells and 
tumor survival or the discovery of tumor associated antigens 
recognized by immune cells. Many studies have highlighted the 
involvement of both innate immunity and adaptive immunity to 
fight against tumor cells. However, cancer cells could escape 
recognition and destruction by the immune system and may 
continue to grow [1, 2]. Thus the formation of a tumor occurs in 
3 phases: an initial elimination phase which coincides with the 
theory of immunosurveillance in which the immune system will 
recognize and destroy cancer cells. A second equilibrium phase 
exists between the development of new cancer cells and their 
destruction. During this phase tumor cells accumulate mutations 
under the pressure exerted by the immune system that will allow 
the emergence of less immunogenic variants which will be 
tolerated by the immune system. The final escape phase during 
which tumor cell variants, with a phenotype edited by the 
immune pressure, are able to evade the innate and adaptive 
defenses and to develop into clinically apparent cancer [1]. At 
this stage, the inflammatory response generated by immune 
cells including the release of cytokines, growth factors and pro-
angiogenic factors to promote tissue reconstruction and the 
intake of nutrients, will be diverted by the tumor to ensure its 
own growth [2]. 
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  The human cytomegalovirus (HCMV) is a multifaceted 
betaherpesvirus that is regarded as asymptomatic, mildly 
pathogenic virus in immunocompetent host. However it may 
cause serious in utero infections as well as acute and chronic 
complications in immunocompromised host [3]. The 
involvement of HCMV in late inflammatory complications 
underscores its possible role in inflammatory diseases and 
cancer. Evidence of this involvement of HCMV in such 
phenomena is being accumulated (review in: [4-6]). Early in 
vitro  studies suggested that HCMV was able to transform 
embryonic fibroblasts in culture and to induce chromosomal 
damages and mutations but HCMV has never been accepted 
as an oncogenic virus [6]. Later on the concept of 
"oncomodulation" was proposed to explain the possible 
contribution of HCMV in tumor progression [7]. The 
oncomodulation states that HCMV infects the tumor tissue 
and acts as a cofactor in amplifying mechanisms of 
carcinogenesis without necessarily initiating tumor. Support 
for this idea is based on experiments showing that proteins of 
HCMV (or non-coding RNAs) could influence the genesis 
and tumor growth acting on the cell cycle, apoptosis, genetic 
instability, invasiveness, angiogenesis, adhesion and cell 
migration. These proteins have been the subject of extensive 
recent reviews [6, 8]. The increased sensitivity of detection 
of HCMV in tumor tissues (immunohistochemistry, in situ 
hybridization and polymerase chain reaction (PCR) 
techniques) originally proposed by Cobbs et al. in 2002 
served to highlight the presence of HCMV proteins and 
DNA in tumor cells but not in adjacent cells of several 
cancers such as glioma [9], colon cancer [10], prostate 
cancer [11], and some skin cancers [12]. Interestingly, the 
presence of HCMV was also highlighted in the pre-
cancerous lesions such as colorectal polyps [10], and 
prostatic intraepithelial neoplasia [11]. The involvement of 
(virus-induced) inflammation in the initiation of cancer has 
emerged in the recent years [13, 14]. Chronic HCMV 
infection triggers biological responses observed in cancer 
with both stimulation of inflammation and immunosuppress-Immune Escape in HCMV Infection and Oncogenesis  The Open Virology Journal, 2011, Volume 5    61 
ion [15]. Indeed, HCMV persistently infects monocytes/ 
macrophages and induces an unique inflammatory (M1) and 
immunosuppressive (M2) polarization of macrophages [16, 
17]. This atypical M1/M2 phenotype of macrophages is 
associated with the release of cytokines involved in cancer 
initiation or promotion such as IL-6, TNF, and IL-10 [2, 
14]. Moreover, HCMV infection activates transcription 
factors which play a main role in inflammation and 
carcinogenesis such as NF-B and the signal transducer 
and activator of transcription 3 (STAT3) [18, 19]. 
  Despite increasing evidence of the presence of HCMV in 
tumors and its participation in carcinogenesis [4-6], its 
involvement in the crucial stage of the tumor immune escape 
has never really been studied. HCMV is a latent herpesvirus 
that maintains dynamic relationships with the immune 
system and we propose that it has the potential to help the 
tumor cell to evade the first line of host defense and induce a 
state of immune tolerance in which it can grow. We will 
discuss side-by-side the means used by HCMV and the 
tumor cell to escape recognition and destruction by the 
immune system and to generate a state of immune tolerance 
(Table 1). Using similar strategies, the HCMV recruited at 
the inflammatory site generated by the early tumor 
development and also by infecting the tumor cell is able to 
offer additional means to escape the immune system and 
promote its development. Thus we propose a novel 
involvement of HCMV in carcinogenesis, as a critical 
cofactor in the final escape phase from immune surveillance 
resulting in progression to cancer. 
HCMV HELPS TUMORS FOR ESCAPE FROM 
RECOGNITION AND DESTRUCTION BY THE 
IMMUNE SYSTEM 
Impairment in Antigen Processing and Presentation 
  The trigger of cellular adaptive immune response 
depends on antigen processing and presentation to T cells via 
the major histocompatibility complex class I (MHC-I) and 
the MHC class II (MHC-II) molecules. Antigen-presenting 
cells (APCs) present the previously phagocytosed antigens to 
CD4+ T Cells through MHC-II molecules, which may lead 
to trigger either an adaptive response or an immune tolerance 
towards this antigen. MHC-II is formed inside the 
endoplasmic reticulum (ER) by the assembly of  and  
chains associated with a chaperone protein, the invariant 
chain (Ii), which stabilizes the MHC- complex and guides 
its migration through the Golgi apparatus until the cell 
surface. Before reaching the surface, Ii chain is degraded, 
enabling the MHC complex to bind to the antigenic peptide 
and to present it to CD4+ T Cells. MHC-I is expressed by 
every nucleated cell and plays an important role in 
presenting cytosolic antigenic peptides to CD8+ T Cells. The 
MHC-I-peptide complex is formed within the endoplasmic 
reticulum in which the antigenic peptides are translocated by 
the Transporter Associated with Antigen Processing (TAP). 
  The effectiveness of the adaptive immune response 
against tumors depends in part on the ability of tumor cells 
to present tumors associated antigens to T cells through 
MHC molecules [20]. To escape from the recognition of its 
antigens by T Cells, tumor cell has been reported to down 
regulate both antigen processing and presentation   
 
machineries [21, 22]. Moreover, antigenic variations are 
provided by continuous mutations occurring in the cancer 
cell. Thereby, even in the presence of an adaptive immune 
response specifically directed against some of its antigens, 
tumors generate mutant variants not recognized by the 
immune system. Repeats of these antigenic mutations play 
an important role in the formation of the tumor antigenic 
profile [22]. Importantly, impairment in surface expression 
of MHC-I peptide has been noticed in many types of cancers 
and is one of the best-studied mechanisms used by tumor 
cells to escape from immune recognition [23]. Several 
mechanisms involved in the alteration of MHC-I expression 
have been described, including MHC-I gene mutations, 
inhibition of MHC-coding genes expression, impairment in 
antigen binding or peptide transport from the endoplasmic 
reticulum to the cell surface [23, 24]. 
  HCMV has developed immune escape strategies by 
interfering with its antigens processing and presentation 
through MHC [25, 26] (Fig. 1). Thus, latent HCMV 
infection of tumor cells might promote the ability of tumor 
cells to evade immune response. At least four proteins 
encoded by the Unique Short (US) region of HCMV genome 
have been involved in the inhibition of MHC-I expression, 
either by directly acting on MHC-I molecules or by acting on 
MHC-I associated proteins, including TAP and tapasin 
which have both chaperone-like and catalytic functions on 
MHC-I molecules (review in [25, 27]): the protein encoded 
by US3 gene of HCMV (pUS3) binds to and inhibits tapasin, 
leading to retention of MHC-I molecules within the ER, 
whereas proteins pUS2 and pUS11 bind to MHC-I molecules 
and promote their reverse transport from the ER to the 
cytosol where they are degraded. Moreover, pUS6 inhibits 
TAP complex thereby inhibiting peptide translocation from 
the cytosol to the ER. In addition, at least three proteins 
encoded by HCMV inhibit the expression of MHC-II [26] : 
pUS2 protein acts far upstream by specifically binding to the 
HLA-DR -chain of MHC-II, leading to its degradation by 
the proteasome, whereas pUS3 protein affects the MHC-II  
 complex by competing with the Ii chain and retaining it in 
the Golgi. At last, pp65 protein encoded by the gene UL83 
(Unique Long 83) acts downstream by mediating an 
accumulation of MHC-II molecules in perinuclear 
lysosomes, resulting in degradation of the HLA-DR -chain. 
An additional mechanism for MHC-II inhibition is the 
synthesis of an HCMV interleukin-10 homolog (cmvIL-10). 
Human IL-10 has been described to inhibit expression of 
MHC-II to the cell surface [28].  A similar inhibition of 
MHC-II expression was noticed in peripheral blood 
mononuclear cells (PBMC) and monocytes treated with 
cmvIL-10 [29]. 
Blockade of Cytotoxic Activity from Immune Effectors 
Escape from Natural Killer Cells 
  Natural killer (NK) cells are essential effectors of innate 
immunity, with both cytotoxicity and cytokine-producing 
functions [30]. Regulation of NK depends on various 
stimulatory and inhibitory receptors which respond to the 
expression of self-molecules such as MHC-I molecules, 
stress-induced ligands or non-self ligands. Indeed, cells that 
fail to express MHC-I molecules such as virus-infected or  
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tumor cells, are recognized and eliminated by NK cells, 
according to the "missing self" hypothesis [31]. Conversely, 
healthy self-cells which express MHC-I molecules stimulate 
NK inhibitory receptors and are self-tolerated by the immune 
system [30]. 
  Some of NK receptors have been particularly involved in 
the immune surveillance of cancers [32], including four 
stimulatory receptors which constitute the group of Natural 
Cytotoxicity Receptor (NCR): NKp30, NKp44, NKp46, 
NKp80 ; receptors DNAM-1 and NKG2D (Fig. 1). In vitro 
studies have shown that blockade of some receptors among 
NKp30, NKp44, NKp46 or NKp80 with monoclonal 
antibodies inhibited NK cells cytotoxicity against tumor cells 
[33, 34].  DNAM-1 (also called CD226), an adhesion 
molecule whose ligands include CD112 and CD155, also 
seems to play an important antitumor role [35-37].  Its 
ligands are frequently expressed by tumor cells, causing their 
Table 1.  Strategies Used by Tumors and CMV for Immune Escape 
 
Strategy Tumors Ref.  CMV  Ref. 
Impairment in Antigen Processing and Presentation 
Impairment in 
surface 
expression of 
MHC-I  
MHC-I gene mutations, inhibition of MHC-coding 
genes expression, impairment in antigen binding or 
peptide transport from the endoplasmic reticulum to 
the cell surface 
[23]  Directly acting on MHC-I molecules or by acting on 
MHC-I associated proteins, including TAP and 
tapasin 
[25, 27] 
Escape from Natural Killer Cells 
Immune surveillance of cancer through NKG2D/ 
NKG2DLs pathway 
[32]  Retention of ligands of NKG2D (MICB, ULBP1 
and 2) in ER by gpUL16  
[54, 55] 
Regulation of MICB by cellular miRNA  [64]  Down regulation of MICB by HCMV miR-UL112  [57] 
Intercellular retention of MICA inhibits NK 
cytotoxicity  
[42]  Inhibition and intracellular retention of MICA by 
UL142  
[56, 59] 
Immune surveillance through Natural Cytotoxicity 
Receptors NKp30, NKp44, NKp46, and NKp80  
[32, 33]  Reduced NKp30-mediated killing by pp65  [63] 
NK activating 
receptors 
Anti-tumor response by DNAM-1 [36,  37]  Down-regulation of CD155 expression, a ligand for 
DNAM-1, by gpUL141 
[60] 
Blockade of the inhibitory receptors LIR-1 and 
NKG2A results in increased NK cell cytotoxicity 
[44]  gpUL18 binds with LIR-1 and inhibits LIR-1 
+ NK 
cell activity  
[47, 48]  NK Inhibitory 
receptors 
Expression of “non classical” HLA-E induces a 
decrease in NK responses through interaction with 
CD94/NKG2A  
[24]  Over expression of HLA-E by gpUL40  [52, 53] 
Blockade of Death Receptors-Mediated Apoptosis 
Over-expression of FLIPL,S which act as caspase 8 
inhibitors 
[67]  Expression of FLIP by immediate early 2 (IE2) 
protein 
[84] 
Over-expression of the anti-apoptotic protein Bcl-2  [70] 
Over-expression 
of antiapoptotic 
proteins 
Over-expression of other antiapoptotic Bcl-2 family 
members such as Bcl-x or Mcl-1  
[74, 75] 
Over-expression of Bcl-2 in HCMV infected cells  [10, 85] 
Decreased expression of Fas  
Mutations or deletions in genes encoding Fas and 
TRAIL-R1-R2 
[76] 
[77] 
Inhibition of recruitment of pro-caspase 8 to the 
Death-inducing Signaling Complex (DISC) by 
product of HCMV UL36 gene 
[87]  Inhibition of pro-
apoptotic 
molecules and 
death receptors 
   Inhibition of proapoptotic Bcl-2 family members 
Bax and Bak by product of the HCMV UL37 gene  
[86] 
Escape from Complement Attack 
HCMV upregulates expression of host-encoded 
CRPs resulting in protection from complement-
dependent lysis 
[96, 97]  Complement 
Regulatory 
Proteins (CRPs) 
Expression of CRPs (CD46, CD55, CD59, and 
CD35) was noticed in a wide range of cancer cells 
[91-93] 
HCMV incorporates host cell-derived CRPs, CD55 
and CD59 into its virions  
[98] 
Immune Tolerance Establishment 
Expression of 
interleukin-10 
Increased release of IL-10 in cancers, conferring a 
more invasive phenotype 
[102-108]  HCMV encodes an IL-10 homolog (cmv-IL-10) that 
shares human IL-10 immunomodulatory properties 
[114- 118] 
Expression of 
TGF 
Overexpression of TGF promoted tumor-immune 
escape and was associated with tumor progression 
with worse prognosis. 
[128-131, 
134-136] 
HCMV induced transcription and release of TGF [138-140] Immune Escape in HCMV Infection and Oncogenesis  The Open Virology Journal, 2011, Volume 5    63 
lysis  in vitro by NK cells. Moreover, DNAM-1-deficient 
mice were noticed to have an impaired antitumor response 
and an accelerated tumor growth [38, 39]. NKG2D receptors 
were extensively studied and found to be expressed by 
various cells such as NK cells, CD8+ T cells, -T cells and 
NKT cells [40]. Several NKG2D ligands (NKG2DLs) have 
been characterized including MICA (MHC class I 
polypeptide-related sequence A), MICB, ULBP1 
(cytomegalovirus UL16-Binding Protein 1) and ULBP 2. 
These ligands present structural homology with MHC-I 
molecules but are typically not expressed by healthy-cells. 
Conversely, expression of NKG2DLs was upregulated in 
stressed cells with DNA damages [41]. Numerous studies 
have highlighted the major role played by the NKG2D/ 
NKG2DLs pathway in tumor immune clearance (review in 
[32]). Conversely, altered expression of NKG2DLs by tumor 
cell variants conferred a selective advantage in tumor-
immune escape [42]. Indeed, in a recent study, tumor cells 
expressed higher amounts of NKG2DLs in NKG2D-
deficient than in wild-type mice, suggesting a selection of 
tumor cells with weak expression of NKGDLs due to 
immune pressure mediated by NK cells [43]. To escape from 
NK-mediated lysis, certain tumor cells with a decrease in 
“classical” HLA type-I expression (HLA-A, B and C) were 
demonstrated to express “non classical” HLA type-I 
molecules including HLA-G and HLA-E. Expression of 
HLA-E induced a decrease in NK antitumor responses by 
interacting with the CD94/NKG2A inhibitory receptors [24]. 
Blockade of the inhibitory receptors LIR-1 and NKG2A also 
consistently resulted in increased NK cell cytotoxicity 
against leukemia cells [44]. 
  Because HCMV down-regulates the expression of MHC-
I molecules, HCMV-infected cells should be more 
vulnerable to Natural Killer cell-mediated cytolysis. 
However, clinical studies in patients with defects in NK 
functions as well as experimental studies have highlighted 
that HCMV has developed various mechanisms to evade the 
recognition and destruction mediated by NK cells [45]. 
HCMV encodes proteins such as gpUL18 and gpUL40 that 
impair NK cells responses by stimulating their inhibitory 
receptors. Glycoprotein gpUL18, which has a highly 
structural resemblance to MHC-I molecules, forms a trimeric 
complex by associating with 2-microglobulin and cellular 
endogenous peptides. For this reason, gpUL18 was the first 
described viral-MHC homologue with the ability to bind and 
present peptides [46-48]. gpUL18 was shown to bind with 
high affinity to the inhibitory receptors LIR-1 expressed by 
NK cells, monocytes, dendritic cells, B cells and subsets of T 
cells [48, 49]. Despite initial controversial studies, gpUL18 
was recently shown to inhibit LIR-1 
+ NK cell activity [48, 
50, 51]. Moreover, expression of “non classical” MHC-I 
molecules HLA-E is up-regulated by HCMV- encoded 
protein gpUL40. This HLA-E over-expression contributes to 
evade NK-mediated lysis by binding to the NK inhibitory 
receptors CD94/NKG2A [52, 53]. 
  Several HCMV-encoded proteins confer protection from 
NK lysis by inhibiting NK activating receptors. This immune 
modulation was described for HCMV-encoded proteins 
gpUL16, gpUL141, gpUL142, and pp65. Among these 
proteins, effects of gpUL16 were the most studied. gpUL16 
binds to and retains in the ER several ligands of NK   
 
activating receptor NKG2D  such as MHC I-related 
molecules MICB and UL16-binding protein family ULBP1 
and 2 [54, 55]. This decreased expression of NKGDLs due to 
sequestration in the ER reduces NK cell recognition of 
HCMV-infected cells. As mentioned above, NKG2D 
receptors have been described in other immune cells 
including dendritic cells and subsets of T cells. The influence 
of gpUL16 on NKG2D receptors in these cells remains to be 
assessed. In addition, expression of MICA and MICB was 
respectively inhibited by the HCMV-encoded MHC-I-related 
protein gpUL142 and HCMV-microRNA miR-UL112 [56-
59]. Moreover, the UL141 gene product, gpUL141, down-
regulated the expression of CD155, a ligand for NK cell 
activating receptors CD226 (DNAM-1) and CD96 
(TACTILE) [60]. At last, pp65 (ppUL83), the main 
tegument protein of HCMV, was shown to impair the 
activation of NK cells. Relationships between pp65 and the 
immune system are complex because pp65 is both a major 
antigenic target for the immune system and an inhibitor of 
antiviral gene expression in infected cells [61, 62]. pp65 was 
described to act as a ligand for the NK cell activating 
receptor NKp30. However, this interaction between pp65 
and NKp30 did not activate NK cells but instead dissociated 
the linked CD3 chains from NKp30, leading to a decreased 
activation signal and a reduced NKp30-mediated killing. 
Thus, the interaction between pp65 and NKp30 forms an 
original model by which a viral protein inhibits NK cell-
mediated lysis by specifically binding to an activating 
receptor [63]. On one hand HCMV miRNA-UL112 
downregulated MICB, resulting in reduced NK cell mediate 
lysis [57], while on the other hand several cellular miRNAs 
have been reported to be upregulated in certain type of 
cancers and have the ability to regulate MICB [64]. A recent 
report demonstrates synergistic activity of miR-UL112 with 
a cellular miRNA to promote immune evasion during 
HCMV infection [65] but possible synergisms between 
cellular and HCMV miRNAs for immune evasion of tumor 
cell need to be further tested. 
Blockade of Death Receptor-Mediated Apoptosis in Tumor 
Cells 
  Stimulation of the cell membrane death receptor Fas by 
its ligand FasL results in recruitment of the adapter protein 
FADD and activation of caspase 8, which unleashes a 
proteolytic cascade leading to cell death by apoptosis [66]. 
FasL is expressed by activated Cytotoxic T Lymphocytes 
(CTL) that, upon activation, specifically recognize a virus-
infected cell or a tumor cell over-expressing Fas. Activation 
of Fas-FasL pathway enables CTL to exert its cytotoxicity. 
Moreover, apoptosis triggered by Fas-FasL is involved in 
removal of activated lymphocytes which became 
unnecessary and might contribute to autoreactivity. Thereby, 
both Fas and FasL may be expressed by CTL resulting either 
in their cytotoxicity or in their own apoptosis. 
  Tumor cell seems to use this dual property of Fas-FasL-
mediated apoptosis in lymphocytes (target-cells destruction 
and stimulation of their own apoptosis) to its advantage. The 
first strategy used by tumor cells to escape from apoptosis 
induced by immune effector cells is the over-expression of 
anti-apoptotic proteins including proteins FLIP which act as 
caspase 8 inhibitors [67] (Fig. 1). Over-expression of FLIP  
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by tumor cells has been described in several cancers such as 
melanoma [68] and EBV-induced lymphomas [69]. 
Similarly, over-expression of the anti-apoptotic protein Bcl-2 
has been involved in the resistance to both extrinsic and 
intrinsic apoptosis by tumor cells [70]. Some studies have 
shown a correlation between over-expression of Bcl-2 in 
lymphoblastic or leukemic cells and prognosis of survival or 
response to chemotherapy [71-73]. Moreover, similar results 
were obtained by studying the expression of other anti-
apoptotic members of Bcl-2 family such as Bcl-x or Mcl-1 
by tumor cells [74, 75]. A second mechanism used by tumor 
cells to resist to apoptosis is the inhibition of pro-apoptotic 
molecules and death receptors. Decreased expression of Fas 
was shown in tumor cells from hepatocellular carcinoma, 
colon cancer or melanoma [76].  Moreover, mutations or 
deletions in genes encoding Fas and TRAIL-R1-R2 were 
noticed in some cancer cells and involved in some familial 
forms of cancers [76, 77]. Many studies have suggested that 
tumor cells could escape from the immune system by 
expressing FasL and inducing apoptosis in activated Fas
+ 
CTL. This phenomena has been referred to as a 
"counterattack" from tumor cells to CTL [76, 78, 79]. 
However, this attractive hypothesis was controversial in 
other studies which did not highlight FasL expression by 
tumor cells [80].  In fact, environmental factors and FasL 
expression levels seem to play an important role to 
determine which of the CTL or the tumor cell "will kill the 
other one." Indeed, in the presence of a pro-inflammatory 
environment, an infiltrate of neutrophils or a high level of 
FasL expression, CTL would kill tumor cells through the 
Fas-FasL pathway. Conversely, in the presence of 
immunosuppressive cytokines such as transforming growth 
factor- (TGF-) or low levels of FasL, CTL express Fas (as 
observed during last steps of acute inflammatory reactions) 
and would be the targets of apoptosis triggered by FasL 
expressed or secreted in a soluble form by the tumor cells 
[22, 81, 82]. 
  Signaling pathways mediated by tumor necrosis factor 
(TNF) superfamily have various roles in apoptosis or 
immune response that impair the survival of latent viruses 
such as herpesviruses. Thereby, many viruses have 
developed strategies to escape from the immune system and 
from the apoptosis of infected cells. Indeed, herpesviruses, 
including HCMV, inhibit TNF receptors signaling pathways 
in different points (recent review in [83]). At first, HCMV 
has been shown to stimulate anti-apoptotic factors which 
downregulate death receptor-mediated pathways (Fig. 1). 
Thus, HCMV immediate early 2 (IE2) proteins have been 
described to activate the expression of FLIP which inhibits 
 
Fig. (1). Model for immune escape in tumors and CMV infection. 
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death receptor-mediated apoptosis [84]. Similarly, over-
expression of Bcl-2 and chemotherapy resistance was 
reported in cultured cells of neuroblastoma or colon cancer 
infected by HCMV [10, 85]. Moreover, besides pro-
apoptotic factors modulated by HCMV such as p53 [6], 
HCMV inhibits the recruitment, the activation or the 
expression of pro-apoptotic actors of death-receptor-
mediated pathways. Indeed, the protein encoded by HCMV 
UL36 gene binds to the pro-caspase 8 and prevents its 
recruitment to the Death-inducing Signaling Complex 
(DISC), whereas a product of the HCMV UL37 gene 
(pUL37x1) inhibits pro-apoptotic Bcl-2 family members Bax 
and Bak leading to the blockade of mitochondrial membrane 
permeabilization and release of cytochrome c [86, 87]. As 
described for tumor cells, HCMV-infected cells were 
suggested to evade from the immune system by triggering 
the apoptosis of CTL recruited on infectious site. In favor of 
this hypothesis, the HCMV Immediate Early protein IE2 was 
shown to enhance the expression (or secretion) of FasL in 
HCMV-infected human retinal cells leading to Fas-
dependent apoptosis of T lymphocytes [88]. Thus, as 
suggested with the "attack and counterattack hypothesis" for 
tumor cells, HCMV-infected cells might have the dual 
properties of blocking their own death and stimulating Fas-
dependent apoptosis of effective T cells. 
Escape from Complement Attack 
  The complement system represents an important effector 
of the innate defense against pathogens. Activation of 
complement leads to opsonization and lysis of pathogens and 
promote an inflammatory response through the production of 
anaphylatoxins [89]. Through this dual involvement in innate 
immunity and inflammation, the action of complement might 
be both favorable and unfavorable towards carcinogenesis 
[90]. Although the presence and the activation of 
complement proteins have been noticed in many cancers, 
their contribution in tumor destruction seems weak. Indeed, 
tumors cells might escape to complement attack by using 
various protective mechanisms such as over-expression of 
membrane-bound Complement Regulatory Proteins (CRPs) 
and secretion of soluble complement inhibitors [90] (Fig. 1). 
Expression of CRPs (CD46, CD55, CD59, and CD35) was 
noticed in a wide range of cancer cells and cell lines 
including renal tumor cell lines and proximal tubular 
epithelial cells [91], endometrial malignant cells [92], and 
colorectal cancers [93]. Furthermore, membrane-associated 
CRPs on tumor cells were shown to decrease the efficacy of 
anti-cancer therapy using monoclonal antibodies by 
impairing both complement-dependent cytotoxicity (CDC) 
and antibody-dependent cell-mediated cytotoxicity (ADCC). 
Different models were proposed to enhance monoclonal 
antibodies treatments by blocking CRPs [90, 94]. 
  To protect the infected cells from complement-mediated 
lysis, several members of the Herpesviridae and Poxviridae 
families were shown to encode homologues of Complement 
Regulatory Proteins (CRPs) [95]. However, no CRPs 
homologue encoded by HCMV has been identified so far. 
Nevertheless, HCMV-infected cells were shown to resist to 
complement attack by several mechanisms: on the one hand, 
HCMV upregulated the expression of two host-encoded 
complement regulatory proteins, CD46 and CD55, in 
fibroblasts and glioblastoma cells, that might in part be 
explained by the identification of a CMV-responsive element 
within the CD46 promoter [96, 97]. On the other hand, 
HCMV incorporates into its virions host cell-derived 
complement regulatory proteins CD55 and CD59. Blockade 
of CD55 by antibodies restored complement-mediated 
effects and reduced viral titers in vitro, indicating an 
important role of complement inhibition for HCMV 
replication [98]. 
HCMV, CANCERS AND IMMUNE TOLERANCE 
ESTABLISHMENT 
  Defect in anti-tumor immunity against tumor cells and 
tumor associated antigens is not simply due to a passive 
process during which the tumor would escape from 
recognition and destruction by the immune system. An 
active process of immune tolerance is set up, involving a 
microenvironment rich in biological tolerogenic agents such 
as cytokines, immature or dysfunctional antigen-presenting 
cells (APCs), and regulatory T cells (Treg). Thereby, 
although tumor associated antigens might be recognized by 
specific T cells, those will be directed to the ways of 
tolerance and anergy [22, 99]. Among the biologically active 
agents released by tumor or stroma cells that may promote 
immunosuppression and immune escape, we will limit 
ourselves to the review of interleukin 10 and TGF-, both in 
the tumor environment and in the HCMV-infected cell. 
Interleukin-10 
  IL-10 has immunosuppressive properties on several 
effectors of the immune system. It inhibits Th1 cells 
activation and proliferation as well as pro-inflammatory 
cytokines production by acting on Antigen Presenting Cells 
(in particular macrophages and dendritic cells) [100]. 
Moreover, IL-10 reduces antigen presentation to T Cells by 
inhibiting both MHC-I and MHC-II expression [28, 101]. 
  An increased release of IL-10 has been described during 
cancers. For instance, exposure of dendritic cells to lysates 
from primary myeloma cells leads to production of IL-10 
[102]. Investigation of IL-10 release by melanoma cells 
themselves has shown a preferential expression of IL-10 by 
metastasis-derived cells compared to primary-tumor-derived 
cells that might indicate a more invasive potential of cell 
variants expressing IL-10 [103]. Moreover, expression of 
CD1 (involved in primary immune responses to lipids and 
glycolipids expressed by various tumors) on infiltrating 
dendritic cells was downregulated in metastatic melanomas 
through the secretion of IL-10 [104]. Similarly, IL-10 has 
been involved in the enhancement of liver metastasis and in 
the impairment of antitumor immunity in murine models of 
colon cancer [105, 106]. IL-10 was also overproduced and 
acted as a growth factor for metastatic B-cell lymphoma in 
rats [107]. Moreover, decreased levels of IL-10 (and TGF-B) 
induced by low-dose of cyclophosphamide were shown to 
restore lymphoproliferative immune response in a tumor-
bearing rat model [108]. IL-10 is also a critical cytokine for 
the differentiation of naïve CD4+ T cells into inducible Type 
1 T regulatory cells (Tr1) [109]. Expansion of functional T 
regulatory cells (including FoxP3+ Tregs and Tr1) during 
cancers, described both in the peripheral blood and in the 
tumor microenvironment, appears to constitute a crucial 
means of tumor immune escape [110, 111]. Like other 66    The Open Virology Journal, 2011, Volume 5  Lepiller et al. 
subtypes of Tregs, Tr1 have been involved in the decrease of 
antitumor immunity and in cancer progression [112, 113]. 
  HCMV encodes an IL-10 homolog, cmvIL-10, that binds 
to the human IL-10 receptor and competes with cellular IL-
10 for binding sites [114, 115]. CmvIL-10 has been described to 
exert immunosuppressive effects by inhibiting production of 
pro-inflammatory cytokines by peripheral blood mononuclear 
cells (PBMC) and dendritic cells and was involved in the 
immune evasion of HCMV-infected cells. CmvIL-10 was 
also shown to modulate the expression of MHC-class I and II 
molecules, and the expression of costimulatory factors and 
cytokines production by PBMC and dendritic cells [29, 116-
118]. Interestingly, cmvIL-10 has been described to activate 
STAT3 in monocytes and HeLa cells [119, 120]. STAT3 
appears to be a central transcription factor in carcinogenesis. 
Indeed, STAT3 is constitutively activated in many cancers 
and plays multiple roles in survival, angiogenesis, cell 
proliferation and metastasis [121]. Furthermore, STAT3 has 
been involved in restraining antitumor immunity by acting 
on both innate and adaptative responses and proposed to play 
a key role in mediating tumor-immune escape [122, 123]. In 
addition, IL-10 production has been reported during HCMV 
infection of THP-1 cells [124] and primary macrophages 
[125]. 
TGF- 
  Transforming growth factor TGF- is a pleiotropic 
immunosuppressive cytokine that promotes immune 
tolerance. TGF- reduces adaptative immune responses by 
inhibiting T cells activation, differentiation and proliferation 
[126]. Moreover, TGF- inhibits effector functions of 
cytotoxic T lymphocytes (CTLs) and tumor infiltrating 
lymphocytes (TILs) by repressing the expression of cytolytic 
gene products such as perforin, granzymes A and B, FasL or 
IFN- [127, 128]. In a murine model, overexpression of 
TGF- in a highly immunogenic tumor was shown to 
promote tumor- immune escape [129]. Conversely, blockade 
of TGF- restored T cells cytotoxicity and tumor clearance 
in several tumor models [128, 130, 131]. Interestingly, TGF-
 might also have a major immunosuppressive and 
tolerogenic activity by promoting the differentiation of naive 
T cells into inductible FoxP3 + Cells [126, 132, 133]. In 
vivo, highly TGF- plasma levels have been associated with 
worse prognosis or increased tumor progression in several 
cancers including breast and prostate cancers [134, 135]. 
Interestingly, recent studies suggested that 
immunotherapeutic approaches targeting TGF- would 
restore an effective antitumor immune response and reduce 
tumor growth [136, 137]. 
 In  vitro early studies highlighted that HCMV could 
induce transcription and secretion of TGF-, in part through 
HCMV Immediate Early proteins [138, 139]. Moreover, 
HCMV infection of endothelial cells induced an integrin 
v6 (a TGF- activator ) expression, leading to up-
regulation of TGF- [140]. In the same study, over 
expression of integrin v6 was noticed in diverse human 
HCMV-infected tissues including lung, placenta, and 
salivary glands. Two recent studies exploring cytokine 
production from transplanted patients described both 
enhanced TGF- plasma levels and overexpression of TGF- 
mRNA in PBMC in patients with acute HCMV infection 
compared to HCMV uninfected patients [141, 142]. 
Interestingly, these studies also noticed overexpression of 
IL-10 mRNA in PBMC and increased soluble FasL plasma 
levels in recipients with active HCMV. In addition, TGF- 
stimulation seems to be beneficial for HCMV. Indeed, TGF-
 increased HCMV replication in cultured human lung 
fibroblasts [143]. Moreover, in cultures of primary murine 
astrocytes infected with murine cytomegalovirus (MCMV), 
release of CMV decreased in the presence of monoclonal 
antibody against TGF- whereas addition of exogenous 
TGF- was followed by an increased release of the virus 
[144]. 
CONCLUSION 
  HCMV has coevolved with the immune system for 
millions of years and has developed a number of strategies to 
counter the possible removal by the immune system. In this 
ongoing tug-of-war, virus gets advantage from 
immunologically poor environment of tumors to avoid 
recognition from immune system. Presence of HCMV DNA 
and proteins in cancerous tissue while absence in adjacent 
healthy tissue indicates the preference of the virus to persist 
in tumors where they are less prone to be removed by the 
immune system. In return, HCMV helps the tumor to avoid 
immune surveillance through encoding viral proteins (and 
possibly through non-coding RNAs) and induction of 
cellular factors having the potential to evade immune 
response and development of immune tolerance conducive 
for tumor development. 
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